October 2026
1. ZHU D, Fang Z, Jin G, Chen J, et al
   Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer.
   Cancer. 2026;132:e70632.
   

   >> Share

   
   
2. HORNER M, Hartmann S, Adkins DR, Uppaluri R, et al
   Perioperative immunotherapy in head and neck squamous cell carcinoma.
   Cancer. 2026;132:e70642.
   

   >> Share

   
   September 2026
3. LIU Q, Handoko, Li JS, Guo QJ, et al
   A systematic review of international/national guidelines for the management of nasopharyngeal carcinoma: Convergence and divergence of recommendations.
   Cancer. 2026;132:e70604.
   

   >> Share

   
   August 2026
4. OYENUGA M, Goyal S, Hannan LM, Emiloju O, et al
   Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma.
   Cancer. 2026;132:e70571.
   

   >> Share

   
   May 2026
5. KIM TM, Williamson SK, Papadopoulos KP, Hamid O, et al
   Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
   Cancer. 2026;132:e70396.
   

   >> Share

   
   
6. PATEL HV, Laird MC, Crone MD, Hranjec T, et al
   Disability-adjusted life-years from human papillomavirus-related oral cavity and pharynx cancers in US men, 2017-2021.
   Cancer. 2026;132:e70412.
   

   >> Share

   
   April 2026
7. INOUE T, Kono M, Kumai T, Obata K, et al
   Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study.
   Cancer. 2026;132:e70429.
   

   >> Share

   
   March 2026
8. BHATIA A, Chen Z, Zhang Y, Bruce JY, et al
   A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).
   Cancer. 2026;132:e70346.
   

   >> Share

   
   
9. KACHNIC LA, Moughan J, Hong TS, Haddock MG, et al
   Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.
   Cancer. 2026;132:e70345.
   

   >> Share

   
   February 2026
10. YANO Y, Tota JE, Graubard BI, Liao LM, et al
    Etiologic heterogeneity across oral cavity cancers.
    Cancer. 2026;132:e70309.
    

    >> Share

    
    January 2026
11. XIAO Z, Liang Z, Huang H, Qin Y, et al
    Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single-arm, phase 2 clinical trial.
    Cancer. 2026;132:e70257.
    

    >> Share

    
    
12. ZHOU HN, Li T, Peng YN, Li H, et al
    Five-year comparison of magnetic resonance imaging and endoscopy for nasopharyngeal carcinoma detection among high-risk populations undergoing screening.
    Cancer. 2026;132:e70256.
    

    >> Share

    
    
13. MEHTA R, Rivero-Hinojosa S, Dayyani F, Ferguson J, et al
    Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.
    Cancer. 2026;132:e70242.
    

    >> Share

    
    December 2025
14. KARUKONDA P, Czito BG, Duffy E, Uronis HE, et al
    Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED): A single-arm phase 2 trial.
    Cancer. 2025;131:e70213.
    

    >> Share

    
    
15. TRINCONI CUNHA M, Sewastjanow-Silva M, Holsinger FC, Garden AS, et al
    Chemotherapy alone for stage II-IVa laryngeal squamous cell carcinoma: A 20-year follow-up.
    Cancer. 2025;131:e70177.
    

    >> Share

    
    November 2025
16. DUFF AJ, Junkins A, Chen L, Mannion K, et al
    The association between human papillomavirus type 16 seropositivity and oropharyngeal cancer among men living with HIV.
    Cancer. 2025;131:e70167.
    

    >> Share

    
    September 2025
17. NIERENGARTEN MB
    Neoadjuvant immunochemotherapy for nonsurgical HPV-negative head and neck cancer.
    Cancer. 2025;131:e70036.
    

    >> Share

    
    August 2025
18. BAI M, Lu Y, Shen L, Yin X, et al
    Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.
    Cancer. 2025;131:e70046.
    

    >> Share

    
    July 2025
19. NIERENGARTEN MB
    Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer.
    Cancer. 2025;131:e35924.
    

    >> Share

    
    
20. HAUGEN CANGE H, Hogmo A, Sandstrom K, Wennerberg J, et al
    Radiotherapy or surgical treatment of early glottic carcinoma: A population-based study from the Swedish Head and Neck Cancer Register evaluating primary treatment outcomes for patients with T1a/T1b tumors.
    Cancer. 2025;131:e35955.
    

    >> Share

    
    April 2025
21. SAHIN O, Kamel S, Wahid KA, Dede C, et al
    International multispecialty expert physician preoperative identification of extranodal extension in patients with oropharyngeal cancer using computed tomography: Prospective blinded human inter-observer performance evaluation.
    Cancer. 2025;131:e35815.
    

    >> Share

    
    January 2025
22. KHANNA D, Mishra A, Birur P, Shruti T, et al
    A prospective study on diagnostic accuracy of technology-enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India.
    Cancer. 2025;131:e35702.
    

    >> Share

    
    December 2024
23. NGUYEN T, Koric A, Chang CE, Barul C, et al
    Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.
    Cancer. 2024 Dec 23. doi: 10.1002/cncr.35620.
    

    >> Share

    
    
24. NIERENGARTEN MB
    First person profile: Quynh-Thu Le, MD: Dr Le confronts the difficult challenges of improving the efficacy and safety of radiation therapy in the treatment of head and neck cancers.
    Cancer. 2024;130:4164.
    

    >> Share

    
    
25. ABYANEH R, Ghalehtaki R, Sanford NN
    Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: A review.
    Cancer. 2024;130:4040-4051.
    

    >> Share

    
    
26. NIERENGARTEN MB
    Promising long-term disease control and survival with pembrolizumab and cabozantinib for head and neck cancer.
    Cancer. 2024;130:3947.
    

    >> Share

    
    
27. NIERENGARTEN MB
    Increased head and neck cancer linked to cannabis use.
    Cancer. 2024;130:3946.
    

    >> Share

    
    November 2024
28. DAY AT, Mitchell DN, Eary RL, Jones E, et al
    Considerations in screening for asymptomatic carotid artery stenosis in irradiated head and neck cancer survivors.
    Cancer. 2024 Nov 26. doi: 10.1002/cncr.35639.
    

    >> Share

    
    
29. BERZENJI D, Oude Booijink ORG, Gahrmann R, Mast H, et al
    A comprehensive approach to defining the cutoff value of oligometastasis in head and neck squamous cell carcinoma.
    Cancer. 2024 Nov 5. doi: 10.1002/cncr.35632.
    

    >> Share

    
    August 2024
30. WU Q, Hu C, Feng L, Yang X, et al
    Comprehensive genomic profiling of infiltrative follicular variant of papillary thyroid carcinoma.
    Cancer. 2024 Aug 14. doi: 10.1002/cncr.35517.
    

    >> Share

    
    July 2024
31. SALZ T, Meza AM, Bradshaw PT, Jinna S, et al
    Role of primary care in opioid prescribing for older head and neck cancer survivors.
    Cancer. 2024 Jul 27. doi: 10.1002/cncr.35478.
    

    >> Share

    
    
32. GOODMAN KA, Hotca A, Liu M, Strong VE, et al
    Top advances of the year: Gastroesophageal cancer.
    Cancer. 2024;130:2253-2256.
    

    >> Share

    
    June 2024
33. NIERENGARTEN MB
    First person profile: Everett Vokes, MD: Pioneer of the combination of radiation and chemotherapy as the first line of treatment for head and neck cancer.
    Cancer. 2024;130:2082-2083.
    

    >> Share

    
    
34. NIERENGARTEN MB
    FDA approves first immunotherapy drug for nasopharyngeal carcinoma.
    Cancer. 2024;130:1903.
    

    >> Share

    
    May 2024
35. NING T, Li D, Deng T, Bai Y, et al
    Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
    Cancer. 2024 May 23. doi: 10.1002/cncr.35377.
    

    >> Share

    
    
36. NIERENGARTEN MB
    First person profile: Barbara Burtness, MD: For more than 20 years, she has applied advances in molecular biology to better treat patients with head and neck cancers.
    Cancer. 2024;130:1724.
    

    >> Share

    
    March 2024
37. CONTRERA KJ, Patel MR, Burtness B, Mehra R, et al
    The role of surgery and deescalation for HPV-related oropharyngeal cancer.
    Cancer. 2024 Mar 18. doi: 10.1002/cncr.35287.
    

    >> Share

    
    
38. HO AL, Foster NR, Deraje Vasudeva S, Katabi N, et al
    A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
    Cancer. 2024;130:702-712.
    

    >> Share

    
    February 2024
39. CHOI H, Cho SW, Kim HH, Yi KH, et al
    Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
    Cancer. 2024 Feb 20. doi: 10.1002/cncr.35256.
    

    >> Share

    
    
40. DE ALMEIDA JR, Su JS, Kolarski MM, Truong T, et al
    Development and validation of a novel TNM staging N-classification of oral cavity squamous cell carcinoma.
    Cancer. 2024;130:410-420.
    

    >> Share

    
    January 2024
41. GROSS ND, Seiwert TY
    Neoadjuvant immunotherapy is safe before surgery in head and neck squamous cell carcinoma. Is it time to challenge the standard-of-care?
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35198.
    

    >> Share

    
    
42. NIERENGARTEN MB
    Novel biomarker significantly improves diagnostic accuracy for nasopharyngeal cancer.
    Cancer. 2024;130:172.
    

    >> Share

    
    
43. NIERENGARTEN MB
    Oral health linked to survival in head and neck cancer.
    Cancer. 2024;130:171.
    

    >> Share

    
    December 2023
44. 
    Researchers identify two new subtypes of HPV-associated head and neck cancers.
    Cancer. 2023;129:3842.
    

    >> Share

    
    November 2023
45. PATEL SA, Gibson MK, Deal A, Sheth S, et al
    A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma.
    Cancer. 2023;129:3381-3389.
    

    >> Share

    
    October 2023
46. CARPENTER DJ, Patel P, Niedzwiecki D, Dillon M, et al
    Long-term risk of carotid stenosis and cerebrovascular disease after radiation therapy for head and neck cancer.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35089.
    

    >> Share

    
    
47. MORAND GB, Eskander A, Fu R, de Almeida J, et al
    The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative.
    Cancer. 2023;129:3263-3274.
    

    >> Share

    
    
48. PHILIPS R, Alnemri A, Amin D, Patel J, et al
    Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer.
    Cancer. 2023 Oct 3. doi: 10.1002/cncr.35045.
    

    >> Share

    
    September 2023
49. ZHANG L, San Valentin EMD, John TM, Jenq RR, et al
    Influence of oral microbiome on longitudinal patterns of oral mucositis severity in patients with squamous cell carcinoma of the head and neck.
    Cancer. 2023 Sep 8. doi: 10.1002/cncr.35001.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share